BioSpark Virginia is a competitive live pitch event for Virginia life sciences start-ups, co-sponsored and organized by CvilleBioHub and the University of Virginia Licensing and Ventures Group (LVG). After an [….]
BioSpark Virginia
2nd Annual BioDiscovery Summit
Join CvilleBioHub for the second edition of the BioDiscovery Summit, a thrilling gathering of researchers, entrepreneurs, and life science professionals. This in-person event will take place on Thursday, October 12, [….]
LUMINOAH RAISES $6M TO REVOLUTIONIZE TUBE FEEDING
Luminoah Inc., a medical technology company dedicated to improving the standard of care for patients requiring enteral nutrition, has closed a $6 million Series A funding round led by Fry’s Path Capital, with participation from Sands Capital, CAV Angels, Virginia Venture Partners, and 757 Angels. The funding will be used to complete the development of Luminoah’s portable, data-driven enteral nutrition system.
In Conversation: President and CEO Allen Cunningham and CSO Shaharyar Khan, Rivus Pharmaceuticals
In Conversation: President and CEO Allen Cunningham and CSO Shaharyar Khan, Rivus Pharmaceuticals There’s a tremendous amount of life sciences momentum and excitement emanating from the rapidly emerging Charlottesville biocluster. [….]
Charlottesville’s ZielBio sets sights on $75M raise
Charlottesville’s ZielBio sets sights on $75M raise Email Facebook LinkedIn Twitter
Kimberly Kelly is the founder and CEO of ZielBio.
Meghan McSweeney
By James Shea – Richmond Inno
November 09, 2022, 01:20pm EST
Charlottesville’s ZielBio finalized a $15 million funding round this summer to complete initial trials of a cancer treatment drug it hopes to bring to market in 2024.
The genesis for the company started when founder and CEO Kimberly Kelly was completing a post-doctoral fellowship at Massachusetts General Hospital. She noticed a correlation in some cancers with the progression of cancer-specific plectin, a protein. The protein became more prevalent in part of cancer cells as certain cancers progressed. She began researching ways to target the plectin as a treatment.
Kelly took a position as a professor in biomedical engineering at the University of Virginia and continued her research. She developed a targeted treatment and initially talked to pharmaceutical companies about licensing the technology. Because the approach was new, the companies wanted to see more data. That meant spinning the technology off from the university and seeking private financing.
“The government and the institutions like the universities don’t have the money to do the $10 million for manufacturing and…
Acumen Publishes Phase 1 Trial Design and Clinical Development Plan for ACU193, an Anti-Amyloid Beta Oligomer Antibody for Alzheimer’s Disease
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) today announced that it published its development rationale and clinical development plan for ACU193, the first clinical-stage monoclonal antibody that selectively targets toxic soluble amyloid beta oligomers (AβOs). The article was published in the Journal of Prevention of Alzheimer’s Disease and outlines the design of its ongoing Phase 1 INTERCEPT-AD trial for ACU193 and planned criteria for advancing to a Phase 2/3 clinical trial based on recent advancements in clinical research on Alzheimer’s disease.
In Conversation: Dr. Amrie Grammer, Co-founder, President and Chief Scientific Officer, AMPEL Biosolutions
AMPEL Biosolutions (AMPEL), located in Charlottesville, Virginia is a leading personalized precision medicine company developing tools that can help autoimmune and inflammatory disease patients improve their quality of life. AMPEL is one of the exciting companies that have emerged from the Charlottesville (CVille) biohub clustered around the University of Virginia (UVA).
ZielBio to Present New Data Demonstrating Preclinical Efficacy of ZB131 in Cholangiocarcinoma at AACR Annual Meeting 2022
ZielBio, Inc., a clinical stage biotechnology company discovering new treatments for cancer and other serious diseases through its innovative ZielFind drug discovery platform, will present new, preclinical data on the efficacy of its ZB131 drug in cholangiocarcinoma (CCA) models at the American Association for Cancer Research (AACR) Annual Meeting 2022. The conference will take place April 8-13, 2022 in New Orleans and virtually. Dr. Lindsey Brinton, Head of Discovery at ZielBio, will present the data in a talk on Tuesday, April 12 at 3:05 in La Nouvelle Orleans C.
Diffusion Pharmaceuticals Completes Dosing in Altitude Trial
Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most, today announced the final participant has completed dosing in its Altitude Trial.
ZielBio Announces First Patient Dosed in Phase 1/2 Clinical Trial of ZB131, Its Novel Monoclonal Antibody Targeting Cancer Specific Plectin
ZielBio Announces First Patient Dosed in Phase 1/2 Clinical Trial of ZB131, Its Novel Monoclonal Antibody Targeting Cancer Specific Plectin First-in-human, open-label, dose escalation study will evaluate ZB131 in patients [….]